John Connolly, PhD, is the chief scientific officer (CSO) at the Parker Institute for Cancer Immunotherapy (PICI), where he designs and executes PICI’s overall research strategy in close collaboration with the institute’s leadership team, center directors and scientific steering committee.

As a human immunologist, his research interests focus on immune monitoring and immunometabolism. Dr. Connolly previously served as CSO of Tessa Therapeutics, a clinical stage cell therapy company focused on solid tumor immunotherapy, and one of PICI’s strategic partners. He is an associate professor at National University of Singapore and an adjunct associate professor of Immunology at Baylor University, where he served on the Board of Governors for the Institute of Biomedical Sciences.

He is also a senior principal investigator and director for translational immunology at the Institute of Molecular and Cellular Biology (IMCB) A*Star. Additionally, Dr. Connolly serves as director for the IMPACT Program, a multi-disciplinary national initiative focused on building cell therapy manufacturing, clinical and regulatory capability for Singapore.

Dr. Connolly received his PhD in Immunology from Dartmouth Medical School and studied human dendritic cell biology under Dr. Michael Fanger. During this time he was involved in the development of immunotherapeutic preclinical models and clinical trials for glioblastoma multiforme (GBM). He moved to the Baylor Institute for Immunology Research, a fully translational research institute dedicated to rationally designed vaccines against cancer and infectious disease. Dr. Connolly served as the director of Research Initiatives for the Baylor Research Institute, leading a large integrated translational research resource and multi-institutional programs that involved a number of international sites. During his tenure at Baylor, he was the central core facility director of the NIAID Centers for Translational Research on Human Immunology and Biodefense, an NIH-funded consortium of basic, translational research and clinical trials focused on vaccine design. Dr. Connolly is the past president of the Board of Directors of The American Cancer Society in N. Texas and founding director of the Singapore Immunology Network’s Immunomonitoring Platform.

At just 16 years old, Inaaya Shariq is a two-time osteosarcoma survivor, advocate, and active member of the pediatric cancer community. Diagnosed with osteosarcoma in her right thigh at age 11, Inaaya underwent 10 months of chemotherapy and a limb-salvage surgery that included an internal prosthesis and knee replacement. After two years cancer-free, she faced a recurrence at age 14, undergoing additional chemotherapy and a full right-leg amputation with hip disarticulation in April 2024.

Through her experiences, Inaaya has become a passionate voice for pediatric cancer awareness and patient engagement in research. She serves as a member of iCAN Illinois KIDS at Ann & Robert H. Lurie Children’s Hospital and on the MIB Agents 2025 Junior Advisory Board, helping to amplify youth perspectives in cancer advocacy and clinical research. Outside of her advocacy work, Inaaya enjoys reading, writing, swimming, watching movies, and spending time with friends and family.

Tiffany Patrick, MPH, MBA joined Amicus in 2024 and currently serves as Chief Patient Officer. A longtime patient advocacy professional with experience spanning rare disease and oncology, she brings more than 20 years of leadership in the biotechnology industry. Her career has been dedicated to advancing the role of the patient voice —from early research through launch and access—with a focus on innovation and impact. Her forward-thinking leadership earned her a place among PharmaVOICE’s Top 100 innovators in life sciences for 2011.

Before joining Amicus, Ms Patrick held patient advocacy and other leadership roles in small- to mid-size biotechnology companies, led teams within medical communications agencies serving the life sciences industry, and operated a strategic consulting practice advising life science companies on patient engagement. She brings these diverse perspectives to her work with patient organizations around the world, helping to bridge scientific innovation with the lived experiences of patients and families.

Ms Patrick serves as a Strategic Advisor for Global Programs at the Oxalosis and Hyperoxaluria Foundation and is a member of The Max Foundation’s Max Think Tank. She is active across the rare disease and oncology biopharmaceutical landscape, bridging advocacy, development, access, and innovation.

She holds a degree in History from American University, a Master of Public Health from Benedictine University, and a Master of Business Administration from the University of Massachusetts, Amherst.

Steve Levine, MD is a board-certified psychiatrist who has spent his career working across multiple facets of the healthcare system to improve people’s lives through creating access to innovation.

Steve completed internship and residency in psychiatry at New York – Presbyterian Hospital / Weill Cornell Medical Center. He then completed fellowship subspecialty training in psychosomatic medicine / psycho-oncology at Memorial Sloan Kettering Cancer Center/New York – Presbyterian Hospital. Prior to Compass, he led the company he founded in 2010, Actify Neurotherapies, that built new models of care delivery across the US for interventional psychiatry treatments. He has published extensively in both peer-reviewed journals and popular media, presented to both professional and lay audiences around the world, served in leadership roles for professional societies and not-for-profit entities, and received numerous awards for leadership and service.

Jose Jimeno, MD, PhD is a medical oncologist and has extensive experience in oncology drug development and clinical trials. He was instrumental in the development of Yondelis, a drug now approved in over 60 countries including in the United States and E.U. He also contributed to the development and approval of Epirubicin in breast cancer, Amifostine as cytoprotector, and Trimetrexate in pneumocistis carinii pneumonia in HIV patients. He also developed Plitidepsin (Aplidine) from preclinical to pivotal trials in myeloma indication in Australia. Previously, Dr. Jimeno was a co-founder and CEO of Pangaea Biotech, a cancer diagnostics company, and CMO for Promontory Therapeutics. Dr. Jimeno has published over 140 papers in peer reviewed journals on cancer.

Seth Ettenberg, PhD, is the President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2020–2021. Prior to joining BlueRock, Seth was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. Previously, Seth headed the Cambridge Site of Novartis’ Oncology Biotherapeutics, leading strategy, innovation and implementation of drug development projects for Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute. Seth is a member of the Board of Directors for Kano Therapeutics and the 2026 Board of Directors of the Alliance for Regenerative Medicine.

Nicole Murphy is Executive Vice President, Head of Pharmaceutical Operations and Technology of Biogen and joined the Executive Committee in 2022. Ms. Murphy joined Biogen in 2015 and has held senior executive positions, including most recently as Senior Vice President, Head of Global Manufacturing & Technical Operations (GMTO).  In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen’s hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ and prior to the spin-off was the General Manager and Head of Cambridge Site Operations at Biogen. Ms. Murphy has extensive experience in leading Supply Chain, Quality, Process Development, Manufacturing and Engineering functions. Prior to joining Biogen Ms. Murphy spent over 15 years at Amgen.

Ms. Murphy holds an MS in Chemical Engineering, an MBA from Rensselaer Polytechnic Institute, and a BS in Engineering from the University of Massachusetts at Amherst. Ms. Murphy serves on a variety of industry councils and committees.

As the Director of Patient Advocacy for Day One Biopharmaceuticals, Kelli Wright is honored work with patient communities, people living with childhood cancer, caregivers, and non-profit foundations to better understand what it’s like to live with their disease.

With experience and a focus on rare diseases and pediatric oncology, Kelli is passionate about including the patient & caregiver experience into all areas of drug development.

Patient Advocacy is the connecter between patients and families and the teams within Day One. It’s critical to include the patient voice in drug development efforts as the company makes drug development and business decisions. What we do every day will ultimately and directly impact the disease communities we serve.

With a 15+ year non-profit career, Kelli has a deep understanding of the patient needs and experiences. Kelli was the National Director of Strategic Initiatives for CureSearch for Children’s Cancer, driving the strategic program of CureSearch by staying in tune with the barriers in drug development. Kelli learned from innovators in the industry, academic and regulatory space, as well as patients and disease-foundations, to address obstacles and develop action plans to close the communication gaps and reduce duplication of efforts.

Kelli resides in South Carolina with her family. She is passionate about nutrition and enjoys hunting for shark’s teeth on the weekends.

Aiden Flynn is the Senior Vice President of Strategic Statistical Consulting at MMS Holdings. Before joining MMS, he founded and served as CEO of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. Widely regarded as a statistical thought leader, Aiden brings extensive expertise in simulation, innovative and adaptive clinical trial design, and the application of precision medicine strategies.

Aiden has collaborated closely with global regulatory agencies, including the FDA and EMA, to advance the integration of biomarkers into clinical development. He has authored more than 40 publications across peer-reviewed journals and academic texts and is frequently invited to present at major international conferences.

Richard A. Graham, PhD, is a biotechnology executive, serial entrepreneur, and scientific leader with 25+ years of experience advancing transformative medicines across oncology, immunology, inflammation, and respiratory disease. He has held multiple C-suite and executive roles spanning R&D leadership, corporate strategy, fundraising, and enterprise transformation, and has contributed to the development and approval of several therapeutics, including Erivedge™, Kadcyla™, Kyprolis™, Perjeta™, and Yupelri™.

Dr. Graham is Co-Founder and Chairman of TruTechnologies (formerly TruLab), where he helped scale the company start-up to a leading clinical-trial technology platform, culminating in an equity investment from LLR Partners. He also co-founded ParaTress, Inc., guiding scientific vision, company formation, and fundraising for its oversubscribed Series Seed round.  Previously, he co-founded Mirador Therapeutics, helping secure more than $400M in early-stage financing for its precision medicine platform targeting immune-mediated inflammatory and fibrotic diseases.

Earlier, Dr. Graham served as Senior Vice President and Head of R&D at Theravance Biopharma, leading organizational restructuring, investor engagement, and late-stage development strategy. Prior to Theravance, he held scientific leadership roles at Onyx Pharmaceuticals and Genentech, where he guided multiple clinical programs and shaped cross-functional strategy in clinical pharmacology, biomarker science, and translational development.

Dr. Graham has published extensively in peer-reviewed journals and serves as a board member, advisor, and strategic consultant to biotechnology companies and venture capital firms. He holds a BS/MS in Biochemistry from Iowa State University and a PhD in Clinical Pharmacology from the University of North Carolina at Chapel Hill, where he received the 2025 Harold and Carol Kohn Distinguished Alumni Award.

Dr. Kaba is a pharmaceutical physician and executive with over 25 years of experience spanning clinical development, translational research, regulatory strategy and submissions, commercialization planning, and fundraising. His expertise covers a broad range of pharmaceutical products across all stages of development and multiple therapeutic areas, with particular focus in neurology, psychiatry, analgesia, and rare (orphan) indications. He is a board-certified neurologist with an academic background in neuroimmunology and neuro-oncology.